J&J expects up to $3.5 billion in COVID vaccine sales this year -Breaking
[ad_1]
(Reuters) -Johnson & Johnson on Tuesday forecast $3 billion-$3.5 billion in revenue for its COVID-19 vaccine this year, compared to $2.39 billion it generated in 2021, even as the drugmaker faces manufacturing issues and uneven demand for the shot.
The single-dose J&J (NYSE:) shot, once touted as an important tool for vaccinating people living in hard-to-reach areas, has been behind its schedule for deliveries in the United States and Europe.
A Baltimore-based manufacturing facility had quality problems that led to the loss of many millions of dosages.
This forecast is coming at a moment when the company plans to seperate its consumer health division and concentrate on its pharmaceuticals and medical device businesses.
Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this website’s data including quotes, charts, or buy/sell signal information. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.
[ad_2]